In this study, we used CRISPR/Cas9 technology to knock out PCSK6 in pancreatic cancer in vitro and in vivo, aiming to explore the functions of PCSK6 and the corresponding mechanism involved in liver metastasis, to update the knowledge regarding the role of PCSK6-targeted therapeutics in the treatments of the liver metastasis in pancreatic cancer. Here, PCSK6 is linked to familial pancreatic carcinoma.